Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Key Highlights
- ➤Noah Berkowitz appointed Chief Medical Officer of Iovance (IOVA), effective September 30, 2026
- ➤Iovance (IOVA) granted Berkowitz inducement equity awards covering up to 450,000 shares
- ➤Stock options carry a $14.82 exercise price and vest over three years
- ➤Certain restricted stock units may vest upon specified regulatory milestones
Expert Statements
Frederick Vogt, Interim President and Chief Executive Officer of Iovance
“We are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers.”
Frederick Vogt, Interim President and Chief Executive Officer of Iovance
“Noah brings deep experience in global drug development that has led to regulatory approvals across cancer, blood disorders, and cell therapy. His track record will be instrumental as we work to bring TIL therapy to many more patients in new markets, earlier treatment settings, and additional solid tumor cancers.”
Noah Berkowitz, Chief Medical Officer of Iovance
“I am excited to join Iovance at this critical inflection point to explore broader applications for TIL technology in new indications and treatment settings.”
Noah Berkowitz, Chief Medical Officer of Iovance
“The Iovance TIL platform demonstrates remarkable clinical results and represents the new frontier across solid tumors, including next-generation approaches. I look forward to contributing to the Iovance vision to expand the reach of this transformative treatment to patients who need it most.”
PHILADELPHIA, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (CMO), effective September 30, 2026.
“We are pleased to welcome Noah to Iovance as we prepare for important development and regulatory milestones for our TIL platform across multiple solid tumor cancers,” said Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer. “Noah brings deep experience in global drug development that has led to regulatory approvals across cancer, blood disorders, and cell therapy. His track record will be instrumental as we work to bring TIL therapy to many more patients in new markets, earlier treatment settings, and additional solid tumor cancers.”
Get started
Create a free account to read the full story.